UNSPSC 51102821: Bacitracin/neomycin/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102821 Bacitracin/neomycin/polymyxin B is a Commodity code that in practice captures a broader range of pharmaceutical and medical supply procurement than its narrow product name suggests. State and local governments soliciting under this code are actually buying multi-item medical and first aid supplies for emergency response, naloxone and drug deactivation systems for community health, generic pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs. The issuing bodies include city fire departments and emergency response divisions (Tampa Fire Department), county health agencies (Seminole County), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering pharmaceutical contracts on behalf of state and local members (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions).

Recent opportunities cluster in Florida, Texas, and the upper Midwest. Representative solicitations include the City of Tampa's IFB for medical and first aid supplies ($700,000 estimated contract amount, sealed bids due March 13, 2026, designated as a sheltered market with a 5% bid discount for certified Small Local Business Enterprises); Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 safe drug deactivation systems annually, bids due July 26, 2023); the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026, response deadline April 3, 2026, designed to inform future formal procurement strategy); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (proposals due March 26, 2026, contract term two years with optional extensions, effective July 1, 2026). The cooperative purchasing vehicle is active for state and local pharmaceutical procurement, and emergency response supply contracts see regular competitive bidding with firm one-year award periods and renewal options.